|
|
Vaccine Detail
|
β-(1,3)-Glucan–MUC1 Conjugate Vaccine |
| Vaccine Information |
- Vaccine Name: β-(1,3)-Glucan–MUC1 Conjugate Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Conjugate vaccine
- Status: Research
- Host Species for Licensed Use: Mouse
- Antigen: MUC1 (Wang et al., 2018)
- Immunization Route: subcutaneous injection
- Description: A synthetic cancer vaccine candidate consisting of a MUC1 peptide antigen covalently conjugated to ?-(1,3)-glucan polysaccharide via a PEG linker. The ?-glucan component serves dual functions as both an antigen carrier and a self-adjuvant, eliminating the need for external adjuvants. The conjugate self-assembles into uniform nanoparticles (~162 nm) that facilitate antigen delivery. ?-Glucan interacts with dectin-1 and other pattern recognition receptors (CR3, SIGNR1) on myeloid cells, activating both innate and adaptive immunity. MUC1 is a membrane-bound glycoprotein overexpressed on various cancer cells including breast, prostate, and ovarian cancers. In preclinical studies, vaccination elicited 13-fold ? anti-MUC1 IgG antibodies; IgM/IgG (predominantly IgG2b, IgG2b/IgG1 >1, Th1 dominance), cytotoxicity potential; dual immunity activation: IFN-? ~4-fold?, IL-6 ~4-fold? (p<0.01); antibodies reactive against MCF-7 breast cancer cells. Covalent conjugation was essential for immunogenicity; simple mixture of ?-glucan and MUC1 peptide showed no significant immune response (Wang et al., 2018).
|
| Host Response |
|
|
| References |
Wang et al., 2018: Wang H, Yang B, Wang Y, Liu F, Fernández-Tejada A, Dong S. β-Glucan as an immune activator and a carrier in the construction of a synthetic MUC1 vaccine. Chemical communications (Cambridge, England). 2018; 55(2); 253-256. [PubMed: 30534737].
|
|
